Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MINDY lysine 48 deubiquitinase 4 (MINDY4) is an enzyme of the deubiquitinase (DUB) family that specifically removes lysine-48-linked polyubiquitin chains from target proteins, a modification that typically signals proteins for proteasomal degradation[4][1]. MINDY4 is believed to play a role in regulating protein turnover and proteolysis, contributing to cellular proteostasis. It is a member of a newly recognized group of DUBs, the MINDY family, which are selective for K48-linked ubiquitin and are important for fine-tuning protein stability in the cell[1][4]. Mutations in MINDY4 are associated with cone-rod dystrophy 6 and nephrolithiasis[4]. The gene is also known as C7orf67 and FAM188B.
Removal of K48-linked polyubiquitin chains from substrates, counteracting degradation signals targeting proteins for proteasomal degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MINDY lysine 48 deubiquitinase 4 (MINDY4).